Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25312338 | 0.85 | ALDH1A1 (0.50) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25310869 | 0.84 | MAPT (0.50) | AKR1C3MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL12939934 | 0.80 | MAPT (0.58) | AKR1C3MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL29723407 | 0.80 | MAPT (0.71) | MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL22495219 | 0.80 | MAPT (0.71) | MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12004775 | 0.80 | MAPT (0.71) | MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10036155 | 0.80 | SIRT6 (0.63) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL17630781 | 0.80 | MAPT (0.53) | AKR1C3MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1393155 | 0.80 | AKR1C3 (0.68) | AKR1C3MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3486900 | 0.79 | MAPT (0.58) | AKR1C3MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | AKR1C3 845/4885MAPT 16/4885MEN1 311/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | AKR1C3 872/4885MAPT 17/4885MEN1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.